{"entity":{"id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","aka":[],"tldr":"A phase 2 trial of Ibrutinib and Venetoclax in chronic lymphocytic leukaemia, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT05963074 by Janssen Research & Development, LLC, with 333 participants enrolled, started 2024-05-30 and due to reach its primary completion in 2027-12-15. Interventions recorded: Ibrutinib and Venetoclax.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05963074","url":"https://clinicaltrials.gov/study/NCT05963074"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["ibrutinib","venetoclax"],"companies":["johnson-johnson","abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05963074","phase":"2","setting":"Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"Janssen Research & Development, LLC","enrolled":333,"outcomes":[]},"route":"/trials/nct05963074/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}